Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 in Advanced NSCLC
NCT00036920Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2002
- Primary completion
- Aug 2002
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canfosfamide in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: 12-Month Survival Rate. Started Jan 2002; status: completed.
02
Drugs
canfosfamide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00036920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036920.